MULTRYS Drug Patent Profile
✉ Email this page to a colleague
▶ Start for $100
Remove trial restrictions
When do Multrys patents expire, and when can generic versions of Multrys launch?
Multrys is a drug marketed by Am Regent and is included in one NDA.
The generic ingredient in MULTRYS is cupric sulfate; manganese sulfate; selenious acid; zinc sulfate. One supplier is listed for this compound. Additional details are available on the cupric sulfate; manganese sulfate; selenious acid; zinc sulfate profile page.
Summary for MULTRYS
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Formulation / Manufacturing: | see details |
| What excipients (inactive ingredients) are in MULTRYS? | MULTRYS excipients list |
| DailyMed Link: | MULTRYS at DailyMed |
Pharmacology for MULTRYS
| Drug Class | Copper Absorption Inhibitor Paramagnetic Contrast Agent |
| Mechanism of Action | Magnetic Resonance Contrast Activity |
| Physiological Effect | Decreased Copper Ion Absorption |
Anatomical Therapeutic Chemical (ATC) Classes for MULTRYS
US Patents and Regulatory Information for MULTRYS
MULTRYS is protected by zero US patents and one FDA Regulatory Exclusivity.
FDA Regulatory Exclusivity protecting MULTRYS
NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Am Regent | MULTRYS | cupric sulfate; manganese sulfate; selenious acid; zinc sulfate | SOLUTION;INTRAVENOUS | 209376-003 | Jun 30, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
